Kornimate/medical-research-clean huggingface dataset:
a study of endoscopic sleeve gastroplasty for obesity in ulcerative colitis

Conditions: Obesity; Ulcerative Colitis

Summary: the purpose of this research is to gather information on the safety and effectiveness of endoscopic sleeve gastroplasty (esg) for weight loss in a population of obese uc patients undergoing colectomy with eventual ipaa.


Eligibility criteria:
inclusion criteria: * bmi 30-50 kg/m2 for at least 6 months prior to esg * diagnosis of uc with plans to undergo or who have already undergone colectomy as part of a plan to pursue eventual 3-stage ileal pouch anal anastomosis (ipaa) * willing to adhere to the diet and behavior modifications required for esg * able to follow the visit schedule * able to provide informed consent * if female, be either post-menopausal, surgically sterile, or agree to practice birth control during year of study and have negative serum human chorionic gonadotropin (hcg) at screening/baseline exclusion criteria: * prior gastric or bariatric surgery or other alteration to upper gastrointestinal anatomy which would preclude safe or technical performance of esg * current or recent (last six months) gastric or duodenal ulceration * esophageal or gastric varices * significant motility disorder of the esophagus or stomach * large hiatal hernia measuring \>5 cm or ≤ 5 cm and associated with severe gastroesophageal reflux * severe coagulopathy, hepatic insufficiency, or cirrhosis * gastric mass * presence of any other medical condition which precludes safe performance of elective endoscopy such as poor general health and/or history of severe hepatic, cardiac, or pulmonary disease * serious or uncontrolled psychiatric illness which may compromise patient understanding of procedure or compliance with follow-up visits * unwilling to participate in an established diet and behavior modification program, with routine follow-up * ongoing corticosteroid use at a dose of \>5 mg daily * daily use of anti-inflammatory agents such as non-steroidal medications, or anticoagulants without medical supervision * alcohol or drug addiction * females who are pregnant, nursing, or planning pregnancy within the next year * concomitant use of or unwillingness to avoid any use of weight loss medications, weight loss supplements, or weight loss herbal preparations * has a condition or is in a situation which in the investigator's opinion may put the subject at significant risk or may interfere significantly with the subject's participation in the study

Keywords: esg ipaa
medical assistance in dying requests in pain clinic

Conditions: Terminal Diseases; Terminal Care; Chronic Pain; Disability or Chronic Disease Leading to Disablement

Summary: terminally ill patients often suffer existentially. terminally ill patients with existential pain may request medical aid in dying. the canadian government legalized medical assistance in dying (maid) for patients unforeseeable deaths. this prospective observational study examined chronic pain clinic patients' maid requests. the study assessed the patients' life quality and outcomes.

adult patients diagnosed with terminal or severe intractable illnesses frequently endure existential distress. consequently, patients with terminal illnesses who experience existential distress may contemplate or seek medical assistance in dying (maid). in march 2021, the government of canada implemented amendments to the criminal code to authorize medical assistance in dying (maid) for individuals whose natural death is not reasonably foreseeable. this prospective observational study evaluated requests made for maid by patients in the chronic pain clinic setting. the study assessed the quality of life and natural outcomes of the patients.

Eligibility criteria:
inclusion criteria: * adult patients with chronic pain and disability. exclusion criteria: * patients without physical disability.

Keywords: terminal disease physical disability chronic pain
intracorporeal vs. extracorporeal anastomosis in patients undergoing laparoscopic right hemicolectomy for colonic cancer

Conditions: Colon Cancer

Summary: in this study, the investigators will compare extracorporeal anastomosis (ea) with intracorporeal anastomosis (ia) in patients undergoing elective laparoscopic hemicolectomy for right colon cancer.

at odense university hospital, svendborg, current standard treatment for right colon cancer is laparoscopic hemicolectomy with extracorporeal anastomosis (ea). to reduce the risk of adverse events, such as fascial dehiscence and later development of incisional hernia, right hemicolectomy with intracorporeal anastomosis has been introduced. when performing a laparoscopic right hemicolectomy the dissection is carried out intracorporeally and the transection and anastomosis is made extracorporeally (ea technique). for ia technique the cancer bearing segment is resected and the bowel ends joined intracorporeally with laparoscopic technique, and the specimen is then retrieved through a pfannenstiel incision. previous series have shown shorter hospital stay as well as shorter time to bowel recovery in patients treated with ia compared to ea, without increasing the risk of severe complications or compromising the oncological outcome. the aim of this study is to investigate whether ia in patients undergoing right hemicolectomy reduces the overall complication rate compared to ea evaluated by comprehensive complication index (cci) . 51 patients will be enrolled in each group.

Eligibility criteria:
inclusion criteria: * patients diagnosed with right colon cancer * eligible for elective laparoscopic right hemicolectomy with primary anastomosis. * eastern cooperative oncology group (ecog) performance status 0-2 * ct staged t1-t3m0 tumour. exclusion criteria: * pregnancy * mental incompetence * acute right hemicolectomy before the intended elective surgery

Keywords: laparoscopic right hemicolectomy intracorporeal anastomosis extracorporeal anastomosis
collecting information from patients enrolled in the breast specialized program of research excellence

Conditions: Breast Cancer

Summary: rationale: collecting and storing information from patients with cancer to study in the future may help doctors learn more about cancer. purpose: this study is collecting information from patients enrolled in the breast specialized program of research excellence.

objectives: * provide a database for administrative and biostatistical support for the breast specialized program of research excellence. outline: data is collected from patients for future research studies. projected accrual: a total of 535 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: breast cancer
pharmacological treatment targeting endotypic traits of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea of Adult

Summary: this study will conduct 3 intervention trials with 44 different participants in each trial, with 22 participants will undergo in-laboratory overnight polysomnograms (psgs) at one night of medication intervention, and the other 22 at taking placebo (contained starch) 1 h before sleep. three medication regimens will be tested: (1) atomoxetine 80mg combined with oxybutynin 5mg; (2) venlafaxine 37.5mg; and (3) atomoxetine 80mg combined with trazodone 100mg. endotypic traits will be estimated using the phenotyping using polysomnography method. the primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.


Eligibility criteria:
inclusion criteria: * apnea-hypopnea index ≥ 15 hr-¹ exclusion criteria: * the presence of pulmonary, cardiac, neurologic, or other active severe medical or psychiatric diseases * current use of continuous positive airway pressure therapy * use of drugs that might interact with the investigational medication or known to affect sleep during the trial or 1 month before the study * known allergy to the investigational medication * current smoking * heavy alcohol drinking (male \> 14 drinks and women \>7 drinks per week) * pregnant or lactating * periodic limb movement index ≤ 15hr-1 * the presence of sleep-related hypoventilation

Keywords: compensation upper airway taiwan serotonin noradrenaline
study of adherence effects and clinical outcomes of kaletra based hiv antiviral therapy

Conditions: HIV Infection

Summary: the purpose of this study is to evaluate the effects of adherence on hiv antiviral response to treatment regimens containing kaletra or other hiv protease inhibitors.


Eligibility criteria:
inclusion criteria: * subject is documented hiv positive * subject is greater than or equal to 18 years of age. * subject currently on a regimen of either nnrti + 2 nucleoside reverse transcriptase inhibitors nrtis), two or three nrtis who have failed regimen as evidenced by two consecutive viral loads with values over 1,000 copies/ml, the last one within the last three months, or * naïve subjects to arv regimen who are required to begin a pi containing haart regimen, or * subjects who have become intolerant to their current antiretroviral regimen and are required to be changed to a first time pi containing haart regimen. * subject had laboratory testing within the previous three months and the most recent testing demonstrates all of the following: hemoglobin \>8.0 g/dl; absolute neutrophil count \>750 cells/ml; platelet count \>20,000/ml; alt or ast \<3 x upper limit of normal (uln); creatinine \<1.5 x uln; triglycerides \<750 mg/dl. * subjects have no have evidence of grade iii or iv adverse event or laboratory abnormality. exclusion criteria: -

Keywords: hiv infection haart lopinavir ritonavir treatment experienced treatment naive
hypertension control based on home blood pressure

Conditions: Hypertension

Summary: the aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (bp) with different target levels using two classes of drugs. the hosp study is a multicenter, prospective, randomized, open, blinded endpoint study. the study subjects are 40-79 years old hypertensive patients. after a 4 weeks of baseline period, subjects are randomly assigned to (1) modest control group (morning home bp \<140 mmhg) or (2) strict control group (morning home bp \<130 mmhg), and to (a) amlodipine group or (b) losartan group. additional antihypertensive drugs can be used if home bp is not controlled. home bp is measured in the early morning and late evening. the participants will be followed up for 5 years.

the aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (bp) with different target levels using two classes of drugs. the hosp study is a multicenter, prospective, randomized, open, blinded endpoint study. inclusion criteria are 40-79 years old treated or untreated hypertensive patients without serious medical conditions. after a 4 weeks of baseline period, subjects are randomly assigned to (1) modest control group (target morning home bp \<140 mmhg) or (2) strict control group (morning home bp \<130 mmhg), and to (a) amlodipine group (2.5-5 mg od) or (b) losartan group (25-50 mg od). additional antihypertensive drugs (diuretics, beta-blockers and alpha-blockers) can be used if home bp is not controlled. home bp is measured in the early morning and late evening. primary end point is combined cardiovascular events.the participants will be followed up for 5 years.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension exclusion criteria: * severe hypertension (treated with 3 or more antihypertensive drugs) * unable to change antihypertensive drugs to a calcium antagonist or an angiotensin antagonist * serious medical conditions * women who may become to be pregnant

Keywords: antihypertensive therapy home blood pressure systolic blood pressure morning blood pressure calcium antagonist angiotensin receptor antagonist
management of symptomatic uterine fibroids in pregnancy by laparotomic myomectomy: a prospective cohort study

Conditions: Uterine Fibroid; Pregnancy Related

Summary: the frequency of women presenting with a combination of uterine fibroids and pregnancy is in-creasing nowadays. uterine fibroids in pregnancy are an unfavorable condition in themselves and being reactive to hormonal stimuli, tending to grow, can generate symptoms of different lev-els of severity. obstetrics and gynecologists are increasingly faced with the problem of clarifying the management tactics of pregnant patients with symptomatic fibroids, who may see their preg-nancy put at risk by these masses.


Eligibility criteria:
inclusion criteria: * the large and giant size of ufs, which prevent the proper continuation of pregnancy and/or occupy the entire small and large pelvis, as well as invade and/or occupy the abdominal cavity. * circulatory disorders, evidenced by necrosis of the ufs. * atypical localization of ufs (cervical, isthmic, intraligamentary, etc.), which caused pelvic organ dysfunction (dysuric phenomena, tenesmus, impediment to the act of defecation, pelvic pain). exclusion criteria: * refusal of lptm by the patient. * absence of urgent indication for lptm during pregnancy.

Keywords: uterine fibroids pregnancy myomectomy fetal outcomes
a trial of shr0302base in patients with vitiligo

Conditions: Vitiligo

Summary: the purpose of this study is to evaluate the efficacy and safety of shr0302base in participants with nonsegmental vitiligo.


Eligibility criteria:
inclusion criteria: 1. clinically diagnosis of non-segmental vitiligo. 2. the disease has been stable for more than 3 months (90 days) (stable disease is defined as no expansion of the original lesion and no new lesions). 3. subjects and their partners do not plan to have children, do not donate sperm/eggs, and voluntarily use highly effective contraception during the study period until 6 months (female subjects) or 3 months (male subjects) after dosing. female subjects must have a negative serum pregnancy test and be non-lactating. exclusion criteria: 1. subjects diagnosed with segmental, mixed or undifferentiated vitiligo; or previously diagnosed with other skin pigmentation disorders (except nevus halos). 2. conditions at baseline that would interfere with evaluation of vitiligo. 3. participants who have used skin bleaching treatments for past treatment of vitiligo or other pigmented areas. 4. use of protocol-defined treatments within the indicated washout period before baseline.
model for the integral assessment of chronic disease management supported in information technology and communication.

Conditions: Chronic Disease

Summary: controlled and randomized clinical trial with 3 parallel groups (intervention group with a health platform nomhadchronic, phone-based care group, usual care group) developed in the valencia la fe health department. 495 high-complexity chronic patients will be included according to a combined recruitment based on a risk predictive model plus clinical opinion. patients will be followed-up during 12 months in order to evaluate health-related quality of life, mortality, health consumption, health direct cost and treatment satisfaction.


Eligibility criteria:
inclusion criteria: * age ≥18 years old. * high complexity: according to a combined criteria a) predictive model of valencia la fe health department for hospital resources consumption in next 12 months (probability \>95%) and b) risk confirmation by a clinical team with experience on chronic patients management. * participants that accept to participate in the study by the informed consent signature * participants that don't meet any of the exclusion criteria exclusion criteria: * age \<18 años. * participants with cognitive or sensorial difficulties or with insufficient knowledge of one of the 2 official languages of valencian community that, according to the healthcare professional, may affect their study participation. * no residents or temporary residents in the health department * homeless or participants with high-risk of social exclusion. * terminal patients or in palliative care according to the secpal (spanish society of palliative care) criteria . * community-dwelling patients * inability for mobile phone management if there is a caregiver with this capability. * participants without a phone line * non high-complexity chronic patients according to the recruitment healthcare professional. * members of the research team, workers related to the centers implied in the study or any other person directly involved in the study - * first degree consanguinity or similar affinity with the team members. * participants already involved in case management. * participants already participating in clinical trials or experimental trials. * participants that don't accept to participate in the study or not signing the informed consent * participants with a main diagnostic of mental diseases * participants with active oncological diagnosis * participants already following specific interventions for hemodialysis, organ transplanting, day hospital * participants with an infectious chronic disease as unique chronic disease (hiv, bhv (hepatitis b virus)...)
non-inferiority study of aliskiren vs losartan in the treatment of hypertension with hyperuricemia

Conditions: Hypertension,Essential; Hyperuricemia

Summary: this clinical trial aims to evaluate the non-inferiority of aliskiren compared to losartan in the treatment of hypertension combined with hyperuricemia. hypertension and hyperuricemia often coexist and may exacerbate each other, increasing the risk of cardiovascular and renal complications. both aliskiren and losartan are widely used for managing hypertension, but their effects on serum uric acid levels and renal function are not well understood in this patient population. this study will involve 66 participants, randomly assigned to receive either aliskiren (240 mg daily) or losartan (100 mg daily) for a treatment period of 3 months. the primary outcome will be the change in serum uric acid levels before and after treatment. secondary outcomes include changes in blood pressure, kidney function (measured by creatinine levels, egfr), and adverse events. the primary objective is to demonstrate that aliskiren is non-inferior to losartan in lowering serum uric acid levels. additionally, the study will assess whether aliskiren, while effectively managing blood pressure, has a lesser impact on kidney function compared to losartan.


Eligibility criteria:
inclusion criteria: 1. diagnosed with hypertension 2. diagnosed with hyperuricemia 3. serum uric acid levels between 420 μmol/l and 700 μmol/l 4. age between 18 and 80 years 5. able to provide informed consent 6. no history of gout 7. no serious comorbidities such as severe kidney, liver, or cardiovascular diseases exclusion criteria: 1. diagnosis of gout 2. history of secondary hypertension 3. severe organ dysfunction, including liver, kidney, or heart failure 4. history of malignant tumors 5. severe cognitive disorders or mental illness 6. pregnant or breastfeeding women 7. allergy to study medications (aliskiren or losartan) 8. participation in other clinical trials during the study period

Keywords: hypertension hyperuricemia non-inferiority
an evaluation of healthcare providers' adherence to pharmacovigilance practices in an african community

Conditions: Drug Reaction; Drug Hypersensitivity; Drug Abuse; Drug Interaction

Summary: egypt's several regions-rural, mixed, and urban-were given pre-designed surveys pertaining to drug adverse events and the role of pharmacovigilance in detection and reporting. the three sections of the survey were dedicated to studying health care professionals' knowledge concerning pharmacovigilance concepts and practices, as well as demographics and people reported or not reported. the survey also asked more questions regarding adverse occurrences that were reported.


Eligibility criteria:
inclusion criteria: * all health care providers are invited to share in the study * minimum experience required is one year in health carrier. * accept sharing in the study exclusion criteria: * health care providers who refuse to complete all data required in the survey. * fresh experience or participants who left health carrier
memantine-enhanced buprenorphine treatment for opioid-dependent young adults

Conditions: Opioid Dependence

Summary: the purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. the study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.

opiate dependence is an increasing problem among young adults (18-25 years old) whose rates of current use of illicit drugs are generally high (19.7 %)according to data from the 2007 national survey on drug use \& health (substance abuse and mental health services administration 2008). young adults start using heroin around this age range, and more recently have had increasing rates of prescription-type drug use. given that young adults with opiate dependence who are seeking treatment are relatively treatment naïve, have a shorter period of addiction, and are more likely to choose buprenorphine over methadone, developing short-term buprenorphine treatment alternatives to long-term methadone agonist treatment is needed.

Eligibility criteria:
inclusion criteria: * men and women between 18-25 years old * opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of opioid dependence for a consecutive 12 month period and positive urine for opioids exclusion criteria: * current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or tobacco) * serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic disorder) * current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type i disorder and participants with suicidal or homicidal thoughts * women who are pregnant, nursing or refuse to use a reliable form of birth control or refuse monthly pregnancy testing * screening liver function tests (sgot or sgpt) greater than 3 times normal

Keywords: drug abuse
a study to identify differences in gene expression in patients with bicuspid and tricuspid valve disease

Conditions: Aortic Valve Disease

Summary: for this study, blood and tissue samples will be collected in order to perform genetic testing to help researchers gather information about this disease and how and why it affects some patients more than others.

the cause of bicuspid aortic valve (bav) and its associated co morbidities is unknown. there is, however, evidence supporting a genetic cause for the bav, pedigree analysis of familial clustering initially directed investigators to a genetic cause of bav. subsequent studies on bav patients using linkage analysis have demonstrated high heritability. early identification of those patients with bav disease who are at risk for ascending aneurysm formation and its complications may allow early intervention to prevent rupture, dissection and emergent cardiac surgery in at risk patients. conversely, identification of those patients with bavs not at risk for aortic aneurysm formation would delineate which patients do not need close follow up of aortic size or prophylactic ascending aortic replacement at time of aortic valve replacement.

Eligibility criteria:
inclusion criteria: * patients \> or = to 18 years of age * presenting with aortic stenosis and to undergo elective aortic valve replacement or repair with or without aortic aneurysm dilation repair * able to sign informed consent document exclusion criteria: * patients unable to provide informed consent for any reason * patients with predominant aortic regurgitation valve disease * patients with other known connective tissue disorders (such as marfan's syndrome, ehlers-danlos syndrome)

Keywords: aortic valve disease gene expression